Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMalignant neoplasms of respiratory and intrathoracic organsICD-10-CM c37-malignant-neoplasm-of-thymus
    Ask Trek AI about this page

    ICD-10-CM Code For Malignant Neoplasm Of Thymus: Group Overview

    The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code group C37 includes malignant neoplasms arising from the thymus gland, covering primary thymic carcinomas and other malignant thymic tumors that affect mediastinal structures. These ICD-10-CM diagnosis codes are used to document clinical scenarios including tumor staging, local invasion of adjacent thoracic structures, and systemic manifestations related to thymic malignancy. Accurate coding within the ICD-10-CM C37 group supports proper claim adjudication, complete clinical documentation, and appropriate reimbursement.

    Customize your policy alerts

    Sign up for ICD-10-CM Code For Malignant Neoplasm Of Thymus: Group Overview policy alerts

    Get alerted when relevant policies change without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    ICD-10-CM C37: Malignant Neoplasm Of Thymus Overview

    The diagnoses in this group represent malignant tumors originating in the thymus gland within the thoracic cavity, affecting mediastinal structures and immune-related tissues. These neoplasms target the respiratory and intrathoracic organ system and can impact respiratory function and systemic immunity. Accurate coding matters for correct clinical records and can influence reimbursement and utilization review.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    When to Use

    Use a code from this group when documentation indicates a primary malignant neoplasm of the thymus or thymic malignancy identified by imaging, biopsy, or surgical pathology. Select the specific code when clinical records specify laterality, tumor type, or other site-related details required by the International Classification of Diseases, Tenth Revision, Clinical Modification coding conventions.

    ICD-10-CM Codes

    1 rows

    ICD-10-CM CodeDescription
    C37Malignant neoplasm of thymus

    DRG Codes

    8 rows

    DRG CodeDescription
    826Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC
    827Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC
    828Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCC
    829Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures with CC/MCC
    830Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC
    843Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC
    844Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with CC
    845Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses without CC/MCC

    Typical Clinical Scenarios

    • A 58-year-old patient presents to the emergency department with progressive anterior chest pressure, non-pleuritic chest pain, and new-onset dyspnea over several weeks. Imaging (CT chest) reveals an anterior mediastinal mass invading adjacent mediastinal fat and compression of nearby structures consistent with a malignant thymic tumor; a biopsy confirms thymic carcinoma. A diagnosis from this group is assigned to capture the primary malignant neoplasm of the thymus. Typical codes: C37
    • A 45-year-old patient in outpatient oncology follow-up has a recently diagnosed primary thymic malignancy found incidentally on chest imaging for unrelated symptoms; staging workup is underway and plans for multimodality therapy are being discussed. The malignancy of the thymus is the focus of ongoing evaluation and management, so a code from this group is used to document the primary cancer in the medical record and care plan. Typical codes: C37
    • A 67-year-old patient with known thymic malignancy is admitted for management of superior vena cava syndrome caused by tumor compression, presenting with facial swelling, venous distention, and dyspnea. The hospitalization documents the malignant thymic tumor as the underlying cause of the acute intrathoracic complication, warranting assignment of the thymus malignancy code alongside codes for the complication. Typical codes: C37

    Related Codes

    C30-MALIGNANT-NEOPLASM-NASAL-CAVITY-MIDDLE-EAR

    ICD-10-CM Code For Malignant Neoplasm Of Nasal Cavity And Middle Ear: Group Overview

    C31-MALIGNANT-NEOPLASM-ACCESSORY-SINUSES

    ICD-10-CM Code For Malignant Neoplasm Of Accessory Sinuses: Group Overview

    C32-MALIGNANT-NEOPLASM-OF-LARYNX

    ICD-10-CM Code For Malignant Neoplasm Of Larynx: Group Overview

    C33-MALIGNANT-NEOPLASM-OF-TRACHEA

    ICD-10-CM Code For Malignant Neoplasm Of Trachea: Group Overview

    C34-MALIGNANT-NEOPLASM-OF-BRONCHUS-AND-LUNG

    ICD-10-CM Code For Malignant Neoplasm Of Bronchus And Lung: Group Overview

    C38-MALIGNANT-NEOPLASM-HEART-MEDIASTINUM-PLEURA

    ICD-10-CM Code For Malignant Neoplasm Of Heart Mediastinum And Pleura: Group Overview

    C39-MALIGNANT-NEOPLASM-OTHER-ILL-DEFINED-SITES

    ICD-10-CM Code For Malignant Neoplasm Of Other And Ill-Defined Sites In The Respiratory System And Intrathoracic Organs: Group Overview

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.